Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7240807rdf:typepubmed:Citationlld:pubmed
pubmed-article:7240807lifeskim:mentionsumls-concept:C0029348lld:lifeskim
pubmed-article:7240807lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:7240807lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:7240807lifeskim:mentionsumls-concept:C0042210lld:lifeskim
pubmed-article:7240807lifeskim:mentionsumls-concept:C0559546lld:lifeskim
pubmed-article:7240807lifeskim:mentionsumls-concept:C0302523lld:lifeskim
pubmed-article:7240807lifeskim:mentionsumls-concept:C0700325lld:lifeskim
pubmed-article:7240807lifeskim:mentionsumls-concept:C0301872lld:lifeskim
pubmed-article:7240807lifeskim:mentionsumls-concept:C1521738lld:lifeskim
pubmed-article:7240807pubmed:issue5lld:pubmed
pubmed-article:7240807pubmed:dateCreated1981-8-20lld:pubmed
pubmed-article:7240807pubmed:abstractTextA double-blind trial of influenza virus vaccines was initiated in the fall of 1976. One dose of 500 chick cell-agglutinating units of subvirion influenza B vaccine gave negligible adverse reactions in schoolchildren and young adults, whereas whole-virus vaccine caused systemic reactions. Subvirion vaccines induced a complement-fixing antibody response, particularly in children, that returned to near original levels over a two-year period. Levels of hemagglutination-inhibiting (HAI) antibodies induced by the vaccine remained elevated for at least 2.5 years in the absence of natural challenge. When a major epidemic of influenza B occurred in the winter of 1979-1980, the youngest children (originally six to nine years of age) had the highest infection rate (53%); in this group protection was estimated at 44% +/- 17% by serologic evidence of infection. Little vaccine efficacy was demonstrated in older age groups at three years after vaccination, despite the persistence of HAI antibodies induced by the vaccine.lld:pubmed
pubmed-article:7240807pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7240807pubmed:languageenglld:pubmed
pubmed-article:7240807pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7240807pubmed:citationSubsetAIMlld:pubmed
pubmed-article:7240807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7240807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7240807pubmed:statusMEDLINElld:pubmed
pubmed-article:7240807pubmed:monthMaylld:pubmed
pubmed-article:7240807pubmed:issn0022-1899lld:pubmed
pubmed-article:7240807pubmed:authorpubmed-author:CooneyM KMKlld:pubmed
pubmed-article:7240807pubmed:authorpubmed-author:FoxJ PJPlld:pubmed
pubmed-article:7240807pubmed:authorpubmed-author:FoyH MHMlld:pubmed
pubmed-article:7240807pubmed:authorpubmed-author:GREENR OROlld:pubmed
pubmed-article:7240807pubmed:authorpubmed-author:AllanI DIDlld:pubmed
pubmed-article:7240807pubmed:authorpubmed-author:BlumhagenJ...lld:pubmed
pubmed-article:7240807pubmed:issnTypePrintlld:pubmed
pubmed-article:7240807pubmed:volume143lld:pubmed
pubmed-article:7240807pubmed:ownerNLMlld:pubmed
pubmed-article:7240807pubmed:authorsCompleteYlld:pubmed
pubmed-article:7240807pubmed:pagination700-6lld:pubmed
pubmed-article:7240807pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7240807pubmed:meshHeadingpubmed-meshheading:7240807-...lld:pubmed
pubmed-article:7240807pubmed:meshHeadingpubmed-meshheading:7240807-...lld:pubmed
pubmed-article:7240807pubmed:meshHeadingpubmed-meshheading:7240807-...lld:pubmed
pubmed-article:7240807pubmed:meshHeadingpubmed-meshheading:7240807-...lld:pubmed
pubmed-article:7240807pubmed:meshHeadingpubmed-meshheading:7240807-...lld:pubmed
pubmed-article:7240807pubmed:meshHeadingpubmed-meshheading:7240807-...lld:pubmed
pubmed-article:7240807pubmed:meshHeadingpubmed-meshheading:7240807-...lld:pubmed
pubmed-article:7240807pubmed:meshHeadingpubmed-meshheading:7240807-...lld:pubmed
pubmed-article:7240807pubmed:meshHeadingpubmed-meshheading:7240807-...lld:pubmed
pubmed-article:7240807pubmed:meshHeadingpubmed-meshheading:7240807-...lld:pubmed
pubmed-article:7240807pubmed:meshHeadingpubmed-meshheading:7240807-...lld:pubmed
pubmed-article:7240807pubmed:meshHeadingpubmed-meshheading:7240807-...lld:pubmed
pubmed-article:7240807pubmed:year1981lld:pubmed
pubmed-article:7240807pubmed:articleTitleInfluenza B virus vaccines in children and adults: adverse reactions, immune response, and observations in the field.lld:pubmed
pubmed-article:7240807pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7240807pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:7240807pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:7240807pubmed:publicationTypeControlled Clinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7240807lld:pubmed